Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets

The acquisition adds seven commercial products, including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol), and brings more than 100 development and commercial-stage assets. Management frames the deal as creating long-term opportunities to drive growth across a larger pipeline. Overall, the news is supportive of future revenue potential but lacks near-term financial specifics.

Analysis

The acquisition adds seven commercial products, including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol), and brings more than 100 development and commercial-stage assets. Management frames the deal as creating long-term opportunities to drive growth across a larger pipeline. Overall, the news is supportive of future revenue potential but lacks near-term financial specifics.